ECSP088904A - Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina - Google Patents
Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresinaInfo
- Publication number
- ECSP088904A ECSP088904A EC2008008904A ECSP088904A ECSP088904A EC SP088904 A ECSP088904 A EC SP088904A EC 2008008904 A EC2008008904 A EC 2008008904A EC SP088904 A ECSP088904 A EC SP088904A EC SP088904 A ECSP088904 A EC SP088904A
- Authority
- EC
- Ecuador
- Prior art keywords
- vasopresine
- ariltriazolonas
- arilimidazolonas
- receptors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente solicitud se refiere a nuevas 4-arilimidazol-2-onas y 5-aril-1,2-4-triazolonas sustituidas, a procedimientos para su preparación, a su uso solas o en combinaciones para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de fármacos para el tratamiento y/o la prevención de enfermedades, particularmente para el tratamiento y/o la prevención de enfermedades cardiovasculares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006024024A DE102006024024A1 (de) | 2006-05-23 | 2006-05-23 | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088904A true ECSP088904A (es) | 2008-12-30 |
Family
ID=38353593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008904A ECSP088904A (es) | 2006-05-23 | 2008-11-21 | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina |
Country Status (30)
Country | Link |
---|---|
US (2) | US8084481B2 (es) |
EP (1) | EP2027096B8 (es) |
JP (1) | JP5247684B2 (es) |
KR (1) | KR101426574B1 (es) |
CN (1) | CN101495458B (es) |
AR (1) | AR061114A1 (es) |
AU (1) | AU2007253572B9 (es) |
BR (1) | BRPI0711975A2 (es) |
CA (1) | CA2652834C (es) |
DE (1) | DE102006024024A1 (es) |
DK (1) | DK2027096T3 (es) |
DO (1) | DOP2007000102A (es) |
EC (1) | ECSP088904A (es) |
ES (1) | ES2385606T3 (es) |
GT (1) | GT200800250A (es) |
HK (1) | HK1136820A1 (es) |
HN (1) | HN2008001720A (es) |
IL (1) | IL195142A (es) |
MA (1) | MA30500B1 (es) |
MX (1) | MX2008014797A (es) |
PE (1) | PE20080706A1 (es) |
PL (1) | PL2027096T3 (es) |
PT (1) | PT2027096E (es) |
RU (1) | RU2460724C2 (es) |
SV (1) | SV2009003098A (es) |
TN (1) | TNSN08443A1 (es) |
TW (1) | TW200817336A (es) |
UY (1) | UY30364A1 (es) |
WO (1) | WO2007134862A1 (es) |
ZA (1) | ZA200809860B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
CA2740075A1 (en) * | 2008-10-10 | 2010-04-15 | Janssen Pharmaceutica Nv | Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists |
DE102008060967A1 (de) * | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
DE102009013642A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
AU2011219746B2 (en) * | 2010-02-27 | 2015-04-23 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
DE102010040187A1 (de) * | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
SI2623499T1 (sl) | 2010-10-01 | 2015-10-30 | Taisho Pharmaceutical Co., Ltd. | Derivat 1,2,4-triazolona |
CN102260154A (zh) * | 2011-06-10 | 2011-11-30 | 南通职业大学 | 一种医药中间体α-溴代对氯苯丙酮的制备方法 |
CN102875499B (zh) * | 2011-07-12 | 2015-08-19 | 天津药明康德新药开发有限公司 | 3-氨甲基氧杂环丁烷及其有机酸盐的制备方法 |
PL3333164T3 (pl) * | 2011-07-29 | 2023-12-18 | Karyopharm Therapeutics Inc. | Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania |
WO2013062027A1 (ja) * | 2011-10-27 | 2013-05-02 | 大正製薬株式会社 | アゾール誘導体 |
CN104023718B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
BR112014010223B8 (pt) | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica |
KR20230152818A (ko) | 2013-03-15 | 2023-11-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
RU2015139732A (ru) | 2013-03-15 | 2017-04-24 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни |
JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
WO2016010610A2 (en) * | 2014-07-18 | 2016-01-21 | Ohio University | Imidazole and thiazole compositions for modifying biological signaling |
CN107074783B (zh) | 2014-11-03 | 2020-06-05 | 拜耳制药股份公司 | 羟烷基取代的苯基三唑衍生物及其用途 |
GB201504763D0 (en) * | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
EP3452457B1 (en) * | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
WO2019141575A1 (de) | 2018-01-16 | 2019-07-25 | Bayer Aktiengesellschaft | Unterstützung bei der behandlung von herzinsuffizienz |
AU2020221239A1 (en) | 2019-02-12 | 2021-09-16 | Mirum Pharmaceuticals, Inc. | Methods for treating cholestasis |
WO2021127459A1 (en) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
WO2023041422A1 (en) | 2021-09-20 | 2023-03-23 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3042466A1 (de) | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
EP0412594B1 (en) | 1989-07-28 | 1996-01-03 | Merck & Co. Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
US5468448A (en) * | 1989-12-28 | 1995-11-21 | Ciba-Geigy Corporation | Peroxide disinfection method and devices therefor |
DE4107857A1 (de) * | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
IT1251488B (it) | 1991-09-17 | 1995-05-15 | Mini Ricerca Scient Tecnolog | Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida |
RU2116304C1 (ru) * | 1992-04-28 | 1998-07-27 | Такеда Кемикал Индастриз, Лтд. | Производные азола, способ их получения, фармацевтическая композиция |
SK94393A3 (en) | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
US6844005B2 (en) * | 2002-02-25 | 2005-01-18 | Trutek Corp | Electrostatically charged nasal application product with increased strength |
FR2708608B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
DE19741235A1 (de) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
KR20010024748A (ko) | 1997-12-17 | 2001-03-26 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
DE19816882A1 (de) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Triazolone mit neuroprotektiver Wirkung |
DE19914140A1 (de) * | 1999-03-27 | 2000-09-28 | Bayer Ag | Substituierte Benzoylpyrazole |
DE19920791A1 (de) * | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
DE19921424A1 (de) * | 1999-05-08 | 2000-11-09 | Bayer Ag | Substituierte Benzoylketone |
DE19929348A1 (de) | 1999-06-26 | 2000-12-28 | Bayer Ag | Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten |
US6531142B1 (en) * | 1999-08-18 | 2003-03-11 | The Procter & Gamble Company | Stable, electrostatically sprayable topical compositions |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
US20040071757A1 (en) * | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
JP4673295B2 (ja) * | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 単環式アニリドスピロヒダントインcgrp受容体拮抗物質 |
WO2005006892A2 (en) | 2003-06-27 | 2005-01-27 | Berglin Corporation Of Washington | Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits |
CN101001631B (zh) | 2003-07-16 | 2014-08-06 | 特卫华妇女健康有限公司 | 利用连续给予雌激素的避孕方案的激素治疗方法 |
BRPI0508532A (pt) | 2004-03-08 | 2007-08-07 | Wyeth Corp | moduladores do canal de ìon |
US20080139560A1 (en) | 2004-03-08 | 2008-06-12 | Scion Pharmaceuticals, Inc. | Ion Channel Modulators |
BRPI0508510A (pt) | 2004-03-08 | 2007-07-31 | Wyeth Corp | moduladores de canal de ìon |
WO2005105779A1 (en) * | 2004-04-28 | 2005-11-10 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
WO2006066133A2 (en) | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2006117657A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Triazolone derivatives as anti-inflammatory agents |
DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
WO2008052031A2 (en) * | 2006-10-24 | 2008-05-02 | Alcon Research, Ltd. | 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions |
DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
-
2006
- 2006-05-23 DE DE102006024024A patent/DE102006024024A1/de not_active Withdrawn
-
2007
- 2007-05-21 DK DK07725514.9T patent/DK2027096T3/da active
- 2007-05-21 CA CA2652834A patent/CA2652834C/en not_active Expired - Fee Related
- 2007-05-21 WO PCT/EP2007/004615 patent/WO2007134862A1/de active Application Filing
- 2007-05-21 BR BRPI0711975-5A patent/BRPI0711975A2/pt not_active IP Right Cessation
- 2007-05-21 CN CN200780027634.4A patent/CN101495458B/zh not_active Expired - Fee Related
- 2007-05-21 MX MX2008014797A patent/MX2008014797A/es active IP Right Grant
- 2007-05-21 US US12/301,616 patent/US8084481B2/en not_active Expired - Fee Related
- 2007-05-21 KR KR1020087031086A patent/KR101426574B1/ko not_active IP Right Cessation
- 2007-05-21 AU AU2007253572A patent/AU2007253572B9/en not_active Ceased
- 2007-05-21 EP EP07725514A patent/EP2027096B8/de not_active Not-in-force
- 2007-05-21 PL PL07725514T patent/PL2027096T3/pl unknown
- 2007-05-21 JP JP2009511411A patent/JP5247684B2/ja not_active Expired - Fee Related
- 2007-05-21 RU RU2008150598/04A patent/RU2460724C2/ru not_active IP Right Cessation
- 2007-05-22 TW TW096118061A patent/TW200817336A/zh unknown
- 2007-05-22 PE PE2007000627A patent/PE20080706A1/es not_active Application Discontinuation
- 2007-05-23 DO DO2007000102A patent/DOP2007000102A/es unknown
- 2007-05-23 ES ES07725514T patent/ES2385606T3/es active Active
- 2007-05-23 AR ARP070102236A patent/AR061114A1/es not_active Application Discontinuation
- 2007-05-23 PT PT07725514T patent/PT2027096E/pt unknown
- 2007-05-24 UY UY30364A patent/UY30364A1/es not_active Application Discontinuation
-
2008
- 2008-11-06 IL IL195142A patent/IL195142A/en not_active IP Right Cessation
- 2008-11-06 TN TNP2008000443A patent/TNSN08443A1/en unknown
- 2008-11-19 ZA ZA2008/09860A patent/ZA200809860B/en unknown
- 2008-11-20 GT GT200800250A patent/GT200800250A/es unknown
- 2008-11-20 SV SV2008003098A patent/SV2009003098A/es not_active Application Discontinuation
- 2008-11-21 EC EC2008008904A patent/ECSP088904A/es unknown
- 2008-11-21 HN HN2008001720A patent/HN2008001720A/es unknown
- 2008-12-05 MA MA31452A patent/MA30500B1/fr unknown
-
2010
- 2010-01-18 HK HK10100511.8A patent/HK1136820A1/xx not_active IP Right Cessation
-
2011
- 2011-12-26 US US13/337,216 patent/US20130005704A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088904A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
CU20140141A7 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
DOP2007000043A (es) | Derivados de cromanol sustituidos y su uso | |
ECSP077296A (es) | Fenilaminotiazoles sustituidos y su uso | |
CU20120161A7 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas | |
GT200900095A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas. | |
CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
UY31922A (es) | Compuestos | |
HN2009003424A (es) | (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea | |
PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
CR11869A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
CR10449A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina | |
DOP2005000174A (es) | Fenilaminotiazoles sustituidos y su uso | |
CU23951B1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
CU20100260A7 (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos |